Aprea starts Phase Ib/II of APR-246 for MDS

Aprea Therapeutics AB (Solna, Sweden) began an open-label, U.S. Phase Ib/II trial to evaluate APR-246 in about 60 patients with tumor protein p53 (TP53; p53) mutant myelodysplastic syndrome (MDS). The dose-escalation Phase I part will evaluate IV APR-246 at a starting dose of 100 mg/kg plus Vidaza azacitidine to determine the maximum tolerated dose (MTD) to be tested in the Phase II portion. The trial will evaluate overall survival (OS) as its primary endpoint in the Phase II portion...